{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:04:02Z","timestamp":1776870242460,"version":"3.51.2"},"reference-count":325,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.pharmthera.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T07:18:07Z","timestamp":1496474287000},"page":"24-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease"],"prefix":"10.1016","volume":"180","author":[{"given":"S.","family":"Badal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rajnarayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.06.003_bb0005","first-page":"21","article-title":"Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson's disease","author":"Ablat","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3940(01)02065-1","article-title":"Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity","volume":"309","author":"Abood","year":"2001","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0015","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3747\/co.23.3099","article-title":"Integrating cannabis into clinical cancer care","volume":"23","author":"Abrams","year":"2016","journal-title":"Current Oncology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0020","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1074\/jbc.M111.316463","article-title":"Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1\/2 kinase activation","volume":"287","author":"Ahn","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0025","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M112.438804","article-title":"Distinct roles of beta-arrestin 1 and beta-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1)","volume":"288","author":"Ahn","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acs.jnatprod.5b00949","article-title":"Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes","volume":"79","author":"Aizpurua-Olaizola","year":"2016","journal-title":"Journal of Natural Products"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0035","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2003-12-4357","article-title":"The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner","volume":"104","author":"Alberich Jorda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatric Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0045","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.214","article-title":"Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression","volume":"1","author":"Amada","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0301-0082(98)00087-2","article-title":"The effects of cannabinoids on the brain","volume":"58","author":"Ameri","year":"1999","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0055","series-title":"Botanical pharmacognosy \u2014 Microscopic characterization of botanical medicine","author":"American Herbal Pharmacopoeia","year":"2013"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0060","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/np8002673","article-title":"Antibacterial cannabinoids from Cannabis sativa: A structure-activity study","volume":"71","author":"Appendino","year":"2008","journal-title":"Journal of Natural Products"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuint.2010.11.002","article-title":"Cannabinoid receptor 1 induces a biphasic ERK activation via multiprotein signaling complex formation of proximal kinases PKCepsilon, Src, and Fyn in primary neurons","volume":"58","author":"Asimaki","year":"2011","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pbb.2004.01.015","article-title":"Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss","volume":"77","author":"Avraham","year":"2004","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.6026\/97320630011378","article-title":"Molecular docking and pharmacological investigations of rivastigmine-fluoxetine and coumarin-tacrine hybrids against acetyl choline esterase","volume":"11","author":"Babitha","year":"2015","journal-title":"Bioinformation"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0085","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","article-title":"Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mnfr.200900516","article-title":"Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood","volume":"54","author":"Banni","year":"2010","journal-title":"Molecular Nutrition & Food Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0095","doi-asserted-by":"crossref","first-page":"H595","DOI":"10.1152\/ajpheart.00184.2004","article-title":"Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors","volume":"287","author":"Batkai","year":"2004","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00213-002-1144-9","article-title":"Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol","volume":"163","author":"Berrendero","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0925-4439(98)00042-8","article-title":"Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats","volume":"1407","author":"Berrendero","year":"1998","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0115","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0120","first-page":"1051","article-title":"G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes","volume":"5","author":"Bjenning","year":"2004","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0125","first-page":"389","article-title":"Cannabinoid receptor antagonists and obesity","volume":"5","author":"Black","year":"2004","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0130","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(10)61080-X","article-title":"Rimonabant: Obituary for a wonder drug","volume":"376","author":"Boekholdt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1476-5381.2010.00756.x","article-title":"The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice","volume":"160","author":"Bolognini","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0145","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/toxsci\/53.1.2","article-title":"Paracelsus: Herald of modern toxicology","volume":"53","author":"Borzelleca","year":"2000","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0160","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1432-1033.1996.0704p.x","article-title":"Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression","volume":"237","author":"Bouaboula","year":"1996","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0165","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1345\/aph.1E499","article-title":"Rimonabant\u2014A selective CB1 antagonist","volume":"39","author":"Boyd","year":"2005","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2006.10.038","article-title":"5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats","volume":"555","author":"Braida","year":"2007","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-006-0639-1","article-title":"Hallucinatory and rewarding effect of salvinorin A in zebrafish: Kappa-opioid and CB1-cannabinoid receptor involvement","volume":"190","author":"Braida","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0180","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/FBP.0b013e328308f1e6","article-title":"Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 \u2212\/\u2212 mice","volume":"19","author":"Breivogel","year":"2008","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nm.3127","article-title":"Targeting the endocannabinoid system in the treatment of fragile X syndrome","volume":"19","author":"Busquets-Garcia","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-319-20825-1_6","article-title":"Endocannabinoids and the immune system in health and disease","volume":"231","author":"Cabral","year":"2015","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0195","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0200","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1210\/er.2000-0026","article-title":"Insights into G protein structure, function, and regulation","volume":"24","author":"Cabrera-Vera","year":"2003","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0205","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1523\/JNEUROSCI.17-04-01226.1997","article-title":"Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain","volume":"17","author":"Cadas","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/bjp.2008.177","article-title":"Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice","volume":"154","author":"Capasso","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0215","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/bjp.2008.294","article-title":"Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: Cross-talk between kappa-opioid and cannabinoid CB(1) receptors","volume":"155","author":"Capasso","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0220","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.lfs.2005.04.017","article-title":"Rimonabant: The first therapeutically relevant cannabinoid antagonist","volume":"77","author":"Carai","year":"2005","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0225","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","article-title":"The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors","volume":"37","author":"Castillo","year":"2010","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tips.2007.02.004","article-title":"The endocannabinoid system in targeting inflammatory neurodegenerative diseases","volume":"28","author":"Centonze","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0235","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.18632\/oncotarget.2233","article-title":"Cannabinoids as therapeutic agents in cancer: Current status and future implications","volume":"5","author":"Chakravarti","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0240","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cell.2016.08.015","article-title":"Allosteric modulation as a unifying mechanism for receptor function and regulation","volume":"166","author":"Changeux","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0245","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3565(24)39301-2","article-title":"Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism","volume":"293","author":"Chen","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.neuro.29.051605.112834","article-title":"Endocannabinoid-mediated synaptic plasticity in the CNS","volume":"29","author":"Chevaleyre","year":"2006","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0255","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1476-5381.2012.02059.x","article-title":"The antinociceptive triterpene \u03b2-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors","volume":"167","author":"Chicca","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0260","doi-asserted-by":"crossref","first-page":"E112","DOI":"10.1208\/aapsj080113","article-title":"Activation of G-proteins in brain by endogenous and exogenous cannabinoids","volume":"8","author":"Childers","year":"2006","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0265","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1528-1157.1979.tb04816.x","article-title":"The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats","volume":"20","author":"Chiu","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0270","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","article-title":"Peripherally restricted CB1 receptor blockers","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0275","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0280","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0091-3057(82)90418-X","article-title":"Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats","volume":"16","author":"Colasanti","year":"1982","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0285","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: Pharmacology and toxicology","volume":"11","author":"\u010colovi\u0107","year":"2013","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjp.0704466","article-title":"Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat","volume":"135","author":"Conti","year":"2002","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0295","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","article-title":"Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw","volume":"369","author":"Costa","year":"2004","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0300","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cmdc.201100568","article-title":"Chromenopyrazoles: Non-psychoactive and selective CB(1) cannabinoid agonists with peripheral antinociceptive properties","volume":"7","author":"Cumella","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0310","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0149-7634(85)90022-3","article-title":"New concepts in cocaine addiction: The dopamine depletion hypothesis","volume":"9","author":"Dackis","year":"1985","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1742-7843.2005.pto960302.x","article-title":"Molecular modelling of drug targets: The past, the present and the future","volume":"96","author":"Dahl","year":"2005","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neuropharm.2007.06.005","article-title":"Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1\/2 MAP kinase signaling","volume":"54","author":"Daigle","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0325","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/187152709789824615","article-title":"Signal transduction via cannabinoid receptors","volume":"8","author":"Dalton","year":"2009","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0330","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2007.01.093","article-title":"Receptor mechanism and antiemetic activity of structurally diverse cannabinoids against radiation-induced emesis in the Least shrew","volume":"563","author":"Darmani","year":"2007","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-2999(02)02815-7","article-title":"Antiemetic and motor-depressive actions of CP55,940: Cannabinoid CB1 receptor characterization, distribution, and G-protein activation","volume":"459","author":"Darmani","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0340","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/10408449709089896","article-title":"Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil","volume":"27","author":"Das","year":"1997","journal-title":"Critical Reviews in Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0345","doi-asserted-by":"crossref","first-page":"48973","DOI":"10.1074\/jbc.M305697200","article-title":"A predominant role for inhibition of the adenylate cyclase\/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells","volume":"278","author":"Davis","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0350","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2174\/187152710793237485","article-title":"Are anti-angiogenic drugs useful in neurodegenerative disorders?","volume":"9","author":"De Filippis","year":"2010","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0355","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/bjp.2008.211","article-title":"Cannabinoids reduce granuloma-associated angiogenesis in rats by controlling transcription and expression of mast cell protease-5","volume":"154","author":"De Filippis","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0360","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1046\/j.1471-4159.2001.00333.x","article-title":"Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus","volume":"77","author":"Derkinderen","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0365","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0370","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(25)06864-4","article-title":"Cannabinoid pharmacology","volume":"38","author":"Dewey","year":"1986","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2010.11.033","article-title":"The actions of benzophenanthridine alkaloids, piperonyl butoxide and (S)-methoprene at the G-protein coupled cannabinoid CB(1) receptor in vitro","volume":"654","author":"Dhopeshwarkar","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0380","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2009.197","article-title":"CB1 antagonists for obesity\u2014What lessons have we learned from rimonabant?","volume":"5","author":"Di Marzo","year":"2009","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0385","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Di Marzo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0390","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2008.03.001","article-title":"FAAH and anandamide: Is 2-AG really the odd one out?","volume":"29","author":"Di Marzo","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0395","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s13311-015-0374-6","article-title":"The endocannabinoid system and its modulation by phytocannabinoids","volume":"12","author":"Di Marzo","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0400","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.69","article-title":"Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats","volume":"2","author":"Ding","year":"2014","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0410","first-page":"615","article-title":"New drugs and new targets","volume":"17","author":"Doggrell","year":"2004","journal-title":"Drug News & Perspectives"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0415","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.neuropharm.2012.05.008","article-title":"Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: The involvement of cannabinoid system","volume":"63","author":"Dutra","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0420","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0002-9440(10)63558-4","article-title":"Neuroprotective effect of (\u2212)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-d-aspartate-induced retinal neurotoxicity: Involvement of peroxynitrite","volume":"163","author":"El-Remessy","year":"2003","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0425","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejmech.2008.03.040","article-title":"Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity","volume":"44","author":"Fan","year":"2009","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0430","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1179\/1973947813Y.0000000079","article-title":"Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway","volume":"25","author":"Fan","year":"2013","journal-title":"Journal of Chemotherapy"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0435","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/ci5002718","article-title":"Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs","volume":"54","author":"Feng","year":"2014","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0440","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fernandez-Ruiz","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0445","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14728221003709792","article-title":"The endocannabinoid system as a target for the treatment of neuronal damage","volume":"14","author":"Fernandez-Ruiz","year":"2010","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0450","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fernandez-Ruiz","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0455","doi-asserted-by":"crossref","first-page":"1326-e1128","DOI":"10.1111\/j.1365-2982.2009.01369.x","article-title":"Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors","volume":"21","author":"Fichna","year":"2009","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0460","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2004.00131.x","article-title":"Smoking cessation and weight gain","volume":"5","author":"Filozof","year":"2004","journal-title":"Obesity Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01065669","article-title":"Convulsant-anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits","volume":"13","author":"Fish","year":"1983","journal-title":"Behavior Genetics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0470","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/00000542-199711000-00011","article-title":"Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate","volume":"87","author":"Gan","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0475","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0480","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease","volume":"163","author":"Garcia","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0485","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garcia-Arencibia","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0490","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pbb.2005.01.032","article-title":"Endocannabinoid signaling system and brain reward: Emphasis on dopamine","volume":"81","author":"Gardner","year":"2005","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0495","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-016-1269-8","article-title":"Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats","author":"Gawel","year":"2016","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0500","first-page":"H2085","article-title":"Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current","volume":"276","author":"Gebremedhin","year":"1999","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0505","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nn832","article-title":"Postsynaptic endocannabinoid release is critical to long-term depression in the striatum","volume":"5","author":"Gerdeman","year":"2002","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0510","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4161\/cib.1.1.6568","article-title":"Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?","volume":"1","author":"Gertsch","year":"2008","journal-title":"Communicative & Integrative Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0515","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1073\/pnas.0803601105","article-title":"Beta-caryophyllene is a dietary cannabinoid","volume":"105","author":"Gertsch","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0520","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1476-5381.2010.00745.x","article-title":"Phytocannabinoids beyond the cannabis plant \u2014 Do they exist?","volume":"160","author":"Gertsch","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0525","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/10799890600942674","article-title":"New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors","volume":"26","author":"Gertsch","year":"2006","journal-title":"Journal of Receptor and Signal Transduction Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0530","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainres.2006.03.011","article-title":"Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity","volume":"1128","author":"Gilbert","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0535","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0540","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1124\/mol.56.6.1362","article-title":"Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors","volume":"56","author":"Glass","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0545","doi-asserted-by":"crossref","first-page":"36527","DOI":"10.1074\/jbc.M205797200","article-title":"Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase\/protein kinase B pathway","volume":"277","author":"Gomez Del Pulgar","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0550","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0026-895X(24)26516-0","article-title":"Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide","volume":"57","author":"Gonsiorek","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0555","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0885-3924(97)00229-7","article-title":"Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol)","volume":"14","author":"Gonzalez-Rosales","year":"1997","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0560","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0565","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(97)01336-8","article-title":"Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals","volume":"339","author":"Griffin","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0570","first-page":"37","article-title":"A comparative study on some chemical and biological characteristics of various samples of cannabis resin","volume":"14","author":"Grlic","year":"1976","journal-title":"Bulletin on Narcotics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0575","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(01)01313-9","article-title":"HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test","volume":"429","author":"Guhring","year":"2001","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0580","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guindon","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0585","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1476-5381.2011.01327.x","article-title":"The endocannabinoid system and cancer: Therapeutic implication","volume":"163","author":"Guindon","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0590","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.phymed.2008.05.003","article-title":"Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with Echinacea purpurea extract","volume":"15","author":"Guiotto","year":"2008","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0595","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc1188","article-title":"Cannabinoids: Potential anticancer agents","volume":"3","author":"Guzman","year":"2003","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0600","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/JME-14-0219","article-title":"Mutations in the \u2018DRY motif of the CB1 cannabinoid receptor result in biased receptor variants","volume":"54","author":"Gyombolai","year":"2015","journal-title":"Journal of Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0605","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QAI.0b013e31811ed205","article-title":"Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep","volume":"45","author":"Haney","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0610","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanu\u0161","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0615","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s11064-012-0716-2","article-title":"The CB(1) receptor-mediated endocannabinoid signaling and NGF: The novel targets of curcumin","volume":"37","author":"Hassanzadeh","year":"2012","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0620","doi-asserted-by":"crossref","DOI":"10.2174\/1389450117666160112113703","article-title":"The emerging role of the cannabinoid receptor family in peripheral and neuro-immune interactions","author":"Haugh","year":"2016","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0625","first-page":"1","article-title":"Review on clinical studies with cannabis and cannabinoids 2005\u20132009","volume":"5","author":"Hazekamp","year":"2010","journal-title":"Cannabinoids"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0630","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1002\/eji.201040667","article-title":"Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties","volume":"40","author":"Hegde","year":"2010","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0635","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1142493","article-title":"Microfluidic organ-on-chip technology for blood-brain barrier research","volume":"4","author":"van der Helm","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0640","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(96)13308-5","article-title":"The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain","volume":"221","author":"Herzberg","year":"1997","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0645","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jnc.12839","article-title":"Cannabinoid receptor 1 modulates the autophagic flux independent of mTOR- and BECLIN1-complex","volume":"131","author":"Hiebel","year":"2014","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0650","doi-asserted-by":"crossref","first-page":"23731","DOI":"10.1074\/jbc.M212369200","article-title":"Hypersensitization of the orexin 1 receptor by the CB1 receptor: Evidence for cross-talk blocked by the specific CB1 antagonist, SR141716","volume":"278","author":"Hilairet","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0655","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0660","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1528-1167.2010.02523.x","article-title":"Delta(9)-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats","volume":"51","author":"Hill","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0665","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2011.09.002","article-title":"Phytocannabinoids as novel therapeutic agents in CNS disorders","volume":"133","author":"Hill","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0670","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacological Reviews"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.06.003_bb0675","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2004.07.030","article-title":"Cannabinoid physiology and pharmacology: 30years of progress","volume":"47","author":"Howlett","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0680","article-title":"Cannabinoid receptors and signal transduction","author":"Howlett","year":"2000","journal-title":"Landes Bioscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0685","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1124\/mol.53.3.504","article-title":"Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies","volume":"53","author":"Howlett","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0690","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4077\/CJP.2016.BAE366","article-title":"Involvement of TRPV1 in the olfactory bulb in Rimonabant-induced olfactory discrimination deficit","volume":"59","author":"Hu","year":"2016","journal-title":"The Chinese Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0700","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0705","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.bbamem.2006.09.029","article-title":"Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets","volume":"1768","author":"Insel","year":"2007","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0710","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1476-5381.2012.01879.x","article-title":"Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice","volume":"166","author":"Izzo","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0715","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/00207450701239467","article-title":"Influence of central nicotinic receptors on arachidonylcyclopropylamide (ACPA)-induced antinociception in mice","volume":"118","author":"Jafari","year":"2008","journal-title":"The International Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0720","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1523\/JNEUROSCI.19-10-03773.1999","article-title":"Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization","volume":"19","author":"Jin","year":"1999","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0725","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bjp.0707419","article-title":"The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects","volume":"152","author":"Johns","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0730","doi-asserted-by":"crossref","first-page":"E5420","DOI":"10.1073\/pnas.1419901111","article-title":"Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy","volume":"111","author":"Jourdan","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0735","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1073\/pnas.0901515106","article-title":"Identification of intracellular carriers for the endocannabinoid anandamide","volume":"106","author":"Kaczocha","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094200","article-title":"Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia","volume":"9","author":"Kaczocha","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0745","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/hmg\/ddi370","article-title":"Cannabinoid receptor type 2 gene is associated with human osteoporosis","volume":"14","author":"Karsak","year":"2005","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0750","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1124\/mol.104.006882","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk?","volume":"67","author":"Kearn","year":"2005","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0755","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.108.000992","article-title":"Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery","volume":"62","author":"Kenakin","year":"2010","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0760","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.chembiol.2009.09.012","article-title":"Discovery of potent and reversible monoacylglycerol lipase inhibitors","volume":"16","author":"King","year":"2009","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0765","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.19082\/1832","article-title":"The role of medicinal plants in the treatment of diabetes: A systematic review","volume":"8","author":"Kooti","year":"2016","journal-title":"Electronic Physician"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0770","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phymed.2009.10.001","article-title":"Tea catechins' affinity for human cannabinoid receptors","volume":"17","author":"Korte","year":"2010","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0775","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1089\/jmf.2008.0243","article-title":"An examination of anthocyanins' and anthocyanidins' affinity for cannabinoid receptors","volume":"12","author":"Korte","year":"2009","journal-title":"Journal of Medicinal Food"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0780","doi-asserted-by":"crossref","first-page":"44877","DOI":"10.1074\/jbc.M206788200","article-title":"Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides","volume":"277","author":"Kozak","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0785","doi-asserted-by":"crossref","first-page":"R549","DOI":"10.1016\/j.cub.2005.07.005","article-title":"Neurotransmission: Emerging roles of endocannabinoids","volume":"15","author":"Kreitzer","year":"2005","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0790","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1242\/jcs.00902","article-title":"G-protein-coupled receptors at a glance","volume":"116","author":"Kroeze","year":"2003","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0795","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1203\/PDR.0b013e3182276b11","article-title":"Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs","volume":"70","author":"Lafuente","year":"2011","journal-title":"Pediatric Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0800","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.alcohol.2006.08.001","article-title":"SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats","volume":"39","author":"Lallemand","year":"2006","journal-title":"Alcohol"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuropharm.2007.07.004","article-title":"Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats","volume":"54","author":"Lamota","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0810","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1359-6446(05)03427-6","article-title":"Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists","volume":"10","author":"Lange","year":"2005","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0815","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0820","doi-asserted-by":"crossref","first-page":"19144","DOI":"10.1073\/pnas.0509588102","article-title":"The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB(1) receptor coupling to G(q\/11) G proteins","volume":"102","author":"Lauckner","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0825","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.exer.2014.01.019","article-title":"Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration","volume":"120","author":"Lax","year":"2014","journal-title":"Experimental Eye Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0830","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1124\/jpet.106.105247","article-title":"Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma","volume":"318","author":"Ligresti","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0835","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0304-3959(03)00242-2","article-title":"Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats","volume":"105","author":"Lim","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0840","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1167\/iovs.08-2196","article-title":"Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor","volume":"49","author":"Liou","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0845","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/acel.12438","article-title":"CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction","volume":"15","author":"Lipina","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0850","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0022-3565(25)13256-4","article-title":"Pharmacology and stereoselectivity of structurally novel cannabinoids in mice","volume":"247","author":"Little","year":"1988","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2017.06.003_bb0855","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1042\/bj3460835","article-title":"Functional CB1 cannabinoid receptors in human vascular endothelial cells","volume":"346","author":"Liu","year":"2000","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0860","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/C4MD00121D","article-title":"Structure of the cannabinoid receptor 1: Homology modeling of its inactive state and enrichment study based on CB1 antagonist docking","volume":"5","author":"Liu","year":"2014","journal-title":"Medicinal Chemical Communications"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0865","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clim.2006.11.002","article-title":"CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents","volume":"122","author":"Lombard","year":"2007","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0870","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2202-13-87","article-title":"Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex","volume":"13","author":"Long","year":"2012","journal-title":"BMC Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12192-015-0653-5","article-title":"Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes","volume":"21","author":"Lu","year":"2016","journal-title":"Cell Stress & Chaperones"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0880","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1124\/jpet.105.093500","article-title":"A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo","volume":"316","author":"Lunn","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0885","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.plipres.2009.07.001","article-title":"Endocannabinoids: Friends and foes of reproduction","volume":"48","author":"Maccarrone","year":"2009","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0890","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signaling at the periphery: 50years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0895","doi-asserted-by":"crossref","first-page":"13484","DOI":"10.1074\/jbc.275.18.13484","article-title":"Anandamide uptake by human endothelial cells and its regulation by nitric oxide","volume":"275","author":"Maccarrone","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0900","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1476-5381.2011.01277.x","article-title":"Cannabinoid receptor signalling in neurodegenerative diseases: A potential role for membrane fluidity disturbance","volume":"163","author":"Maccarrone","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0905","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.4049\/jimmunol.166.12.7183","article-title":"Progesterone up-regulates anandamide hydrolase in human lymphocytes: Role of cytokines and implications for fertility","volume":"166","author":"Maccarrone","year":"2001","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0910","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.89.9.3825","article-title":"Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells","volume":"89","author":"Mackie","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0915","doi-asserted-by":"crossref","first-page":"6552","DOI":"10.1523\/JNEUROSCI.15-10-06552.1995","article-title":"Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor","volume":"15","author":"Mackie","year":"1995","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0920","series-title":"Symposium on the cannabinoids","first-page":"7","article-title":"[35S]GTP\u03b3S binding to assess inverse agonist actions of ligands at human recombinant CB1 and CB2 receptors","author":"MacLennan","year":"1998"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0925","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1476-5381.2010.01063.x","article-title":"Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action","volume":"162","author":"Maione","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0930","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.neuroscience.2006.11.016","article-title":"Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation","volume":"144","author":"Marchalant","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0935","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137034","article-title":"Potential therapeutic value of a novel FAAH inhibitor for the treatment of anxiety","volume":"10","author":"Marco","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0940","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0945","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.bbamcr.2009.05.002","article-title":"Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: Interactions with muscarinic and \u03b4-opioid receptors","volume":"1793","author":"Marini","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0950","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nn.2601","article-title":"The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors","volume":"13","author":"Marrs","year":"2010","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0955","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease","volume":"79","author":"Martin-Moreno","year":"2011","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0960","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1471-4159.2007.05073.x","article-title":"5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid","volume":"104","author":"Massi","year":"2008","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0965","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0970","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/1535-7163.MCT-07-0371","article-title":"Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells","volume":"6","author":"McAllister","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0975","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1021\/jm0302647","article-title":"An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist\/inverse agonist binding region","volume":"46","author":"McAllister","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0980","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11481-015-9608-y","article-title":"The antitumor activity of plant-derived non-psychoactive cannabinoids","volume":"10","author":"McAllister","year":"2015","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0985","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00008877-200312000-00002","article-title":"The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats","volume":"14","author":"McLaughlin","year":"2003","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0990","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb0995","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1021\/ja00993a072","article-title":"A stereospecific synthesis of (\u2212)-delta 1- and (\u2212)-delta 1(6)-tetrahydrocannabinols","volume":"89","author":"Mechoulam","year":"1967","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1000","doi-asserted-by":"crossref","first-page":"11s","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: An overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1010","article-title":"The influence of safety, efficacy, and medical condition severity on natural v. synthetic drug preference","author":"Meier","year":"2015","journal-title":"Medical Decision Making"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1015","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0026-895X(25)13256-2","article-title":"Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs","volume":"44","author":"Melvin","year":"1993","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1020","first-page":"145","article-title":"Antimicrobial agents from higher plants. An investigation of Hunnemannia fumariaefolia pseudoalcoholates of sanguinarine and chelerythrine","volume":"41","author":"Mitscher","year":"1978","journal-title":"Lloydia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.drudis.2010.03.007","article-title":"Endocannabinoid biosynthesis and inactivation, from simple to complex","volume":"15","author":"Muccioli","year":"2010","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1030","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2174\/0929867054020891","article-title":"Current knowledge on the antagonists and inverse agonists of cannabinoid receptors","volume":"12","author":"Muccioli","year":"2005","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1035","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1021\/bi981767v","article-title":"Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: Structural requirements determined by peptide analysis","volume":"38","author":"Mukhopadhyay","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1045","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1016\/j.febslet.2006.04.102","article-title":"Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats","volume":"580","author":"Murillo-Rodriguez","year":"2006","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pbb.2006.05.018","article-title":"Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice","volume":"84","author":"Nagai","year":"2006","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"Journal of Natural Products"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopsych.2011.11.027","article-title":"beta-Arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner","volume":"71","author":"Nguyen","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.phrs.2013.12.010","article-title":"Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB\/c mice","volume":"80","author":"Nicolussi","year":"2014","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/ICU.0000000000000242","article-title":"Cannabinoids for treatment of glaucoma","volume":"27","author":"Novack","year":"2016","journal-title":"Current Opinion in Ophthalmology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.chembiol.2009.05.004","article-title":"Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins","volume":"16","author":"Oddi","year":"2009","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/1389557054368754","article-title":"CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches","volume":"5","author":"Ortega-Gutierrez","year":"2005","journal-title":"Mini Reviews in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1085","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1100","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/FBP.0b013e32835a7c4d","article-title":"delta(9)-Tetrahydrocannabinol acts as a partial agonist\/antagonist in mice","volume":"23","author":"Paronis","year":"2012","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/jpet.106.101287","article-title":"Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling","volume":"318","author":"Patel","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2221-6189(13)60123-7","article-title":"Medicinal significance, pharmacological activities, and analytical aspects of anthocyanidins \u2018delphinidin\u2019: A concise report","volume":"2","author":"Patel","year":"2013","journal-title":"Journal of Acute Disease"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2146\/060258","article-title":"Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity","volume":"64","author":"Patel","year":"2007","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/cb800264k","article-title":"Functional cell-based screening and saturation transfer double-difference NMR have identified haplosamate A as a cannabinoid receptor agonist","volume":"4","author":"Pereira","year":"2009","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/13556210071252","article-title":"Neuropharmacology and therapeutic potential of cannabinoids","volume":"5","author":"Pertwee","year":"2000","journal-title":"Addiction Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1130","first-page":"1","article-title":"Pharmacological actions of cannabinoids","author":"Pertwee","year":"2005","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.06.003_bb1135","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: The first 66years","volume":"147","author":"Pertwee","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1140","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: An overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: \u0394(9)-tetrahydrocannabinol, cannabidiol and \u0394(9)-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1160","doi-asserted-by":"crossref","first-page":"Pl1","DOI":"10.1016\/S0024-3205(98)00238-0","article-title":"Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors","volume":"63","author":"Petitet","year":"1998","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1165","series-title":"Pfizer discontinues development program for its phase 3 obesity compound (CP-945,598)","volume":"Vol. 2016","author":"Pfizer","year":"2008"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1170","series-title":"Taranabant Taranabant","volume":"Vol. 2016","author":"Pharmacodia","year":"2008"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1175","first-page":"8","article-title":"Anandamide inhibits breast tumor-induced angiogenesis","volume":"10","author":"Picardi","year":"2014","journal-title":"Translational Medicine @UniSa"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1180","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/gast.1997.v113.pm9352881","article-title":"Epidermal growth factor inhibits bombesin-induced activation of phospholipase C-beta1 in rat pancreatic acinar cells","volume":"113","author":"Piiper","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1185","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neuropharm.2005.11.023","article-title":"Modulation of Delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors","volume":"50","author":"Pisanu","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0006-8993(02)03055-X","article-title":"Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: An in vivo microdialysis study","volume":"948","author":"Pistis","year":"2002","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1195","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0022-3565(24)37993-5","article-title":"SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist","volume":"288","author":"Portier","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1200","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1205","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0022-3565(24)36640-6","article-title":"Involvement of Dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord","volume":"281","author":"Pugh","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejmech.2016.05.044","article-title":"Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor","volume":"121","author":"Qiao","year":"2016","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1215","series-title":"Surinabant Sanofi-Aventis discontinued. Sanofi-Aventis S.A stop its clinical trial","volume":"Vol. 2016","author":"R & D Focus Drug News","year":"2008"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1220","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.M601074200","article-title":"Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects","volume":"281","author":"Raduner","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-3-642-41199-1_22","article-title":"Beta-arrestins: Regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia","volume":"219","author":"Raehal","year":"2014","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1230","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1574889810999160719105433","article-title":"Endocannabinoid system in neurological disorders","volume":"10","author":"Ranieri","year":"2016","journal-title":"Recent Patents on CNS Drug Discovery"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1240","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5055\/jom.2009.0033","article-title":"Postoperative analgesia after radical prostatectomy with high-dose intrathecal morphine and intravenous naloxone: A retrospective review","volume":"5","author":"Rebel","year":"2009","journal-title":"Journal of Opioid Management"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1245","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/jcp.25026","article-title":"Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines","volume":"230","author":"Refolo","year":"2015","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1250","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-015-0363-2","article-title":"Pharmacokinetics of cannabis in cancer cachexia-anorexia syndrome","author":"Reuter","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1255","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1046\/j.1471-4159.1998.71041525.x","article-title":"Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes","volume":"71","author":"Rhee","year":"1998","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1260","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0022-3565(24)37266-0","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"Rinaldi-Carmona","year":"1998","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1270","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0024-3205(96)00085-9","article-title":"Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain","volume":"58","author":"Rinaldi-Carmona","year":"1996","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1275","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00001756-199302000-00005","article-title":"Presence of cannabinoid binding sites in the brain from early postnatal ages","volume":"4","author":"Rodriguez de Fonseca","year":"1993","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/17425255.1.2.187","article-title":"Cytochrome P450 interactions in human cancers: New aspects considering CYP1B1","volume":"1","author":"Roos","year":"2005","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1290","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejmech.2014.07.062","article-title":"One-pot heterogeneous synthesis of delta(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors","volume":"85","author":"Rosati","year":"2014","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1295","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjp.0702351","article-title":"Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630","volume":"126","author":"Ross","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1300","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2011.07.030","article-title":"Autophagy and aging","volume":"146","author":"Rubinsztein","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1305","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/mol.58.4.814","article-title":"The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase","volume":"58","author":"Rueda","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1315","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1320","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1325","first-page":"341","article-title":"ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration","volume":"61","author":"Rutkowska","year":"2006","journal-title":"Pharmazie"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1330","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1335","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1340","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1345","first-page":"5784","article-title":"Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor","volume":"61","author":"Sanchez","year":"2001","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1350","series-title":"Sanofi-aventis to discontinue all clinical trials with rimonabant","volume":"Vol. 2016","author":"Sanofi-aventis","year":"2008"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jcpt.12235","article-title":"Phytocannabinoids and epilepsy","volume":"40","author":"dos Santos","year":"2015","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1360","doi-asserted-by":"crossref","DOI":"10.1111\/cen.13120","article-title":"Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome","author":"Sathyapalan","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1365","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1748-1716.2011.02280.x","article-title":"The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors","volume":"204","author":"Savinainen","year":"2012","journal-title":"Acta Physiologica (Oxford, England)"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1370","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/npp.2016.27","article-title":"Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist Rimonabant in squirrel monkeys","volume":"41","author":"Schindler","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1375","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1016\/S0021-9258(17)44667-9","article-title":"Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type","volume":"258","author":"Schmid","year":"1983","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1380","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00213-006-0676-9","article-title":"Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats","volume":"191","author":"Schramm-Sapyta","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1385","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00735.x","article-title":"The endocannabinoid system as a target for the treatment of neurodegenerative disease","volume":"160","author":"Scotter","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/jpet.109.151654","article-title":"The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists\/inverse agonists","volume":"330","author":"Seely","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1395","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1582-4934.2011.01493.x","article-title":"Rapamycin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking the secondary hypoxic response","volume":"16","author":"Sekiguchi","year":"2012","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1400","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature20613","article-title":"High-resolution crystal structure of the human CB1 cannabinoid receptor","volume":"540","author":"Shao","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1405","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.2174\/1381612822666160311115226","article-title":"Polypharmacological properties and therapeutic potential of beta-caryophyllene: A dietary phytocannabinoid of pharmaceutical promise","volume":"22","author":"Sharma","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1410","first-page":"238482","article-title":"Small molecules from nature targeting G-protein coupled cannabinoid receptors: Potential leads for drug discovery and development","volume":"2015","author":"Sharma","year":"2015"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1415","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","article-title":"Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice","volume":"14","author":"Shearman","year":"2003","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1420","doi-asserted-by":"crossref","DOI":"10.1002\/phar.1747","article-title":"Treatment of cannabis use disorder: Current science and future outlook","author":"Sherman","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1425","doi-asserted-by":"crossref","first-page":"33422","DOI":"10.1074\/jbc.M111.261651","article-title":"Identification of essential cannabinoid-binding domains: Structural insights into early dynamic events in receptor activation","volume":"286","author":"Shim","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bip.10424","article-title":"Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction","volume":"71","author":"Shim","year":"2003","journal-title":"Biopolymers"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1435","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1440","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.pain.2011.04.005","article-title":"Activation of cannabinoid receptors by the pentacyclic triterpene alpha,beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice","volume":"152","author":"da Silva","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1445","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1523\/JNEUROSCI.16-24-08057.1996","article-title":"Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain","volume":"16","author":"Sim","year":"1996","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mcne.1998.0714","article-title":"Neurotrophic molecules: Strategies for designing effective therapeutic molecules in neurodegeneration","volume":"12","author":"Skaper","year":"1998","journal-title":"Molecular and Cellular Neurosciences"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00421466","article-title":"Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats","volume":"40","author":"Sofia","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1460","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mce.2014.09.023","article-title":"New insights on food intake control by olfactory processes: The emerging role of the endocannabinoid system","volume":"397","author":"Soria-Gomez","year":"2014","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-8993(97)00403-4","article-title":"Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release","volume":"763","author":"Stefano","year":"1997","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1470","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","article-title":"Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas","volume":"58","author":"Stella","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1475","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1523\/JNEUROSCI.21-17-06475.2001","article-title":"Neuroprotection by delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity","volume":"21","author":"van der Stelt","year":"2001","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1485","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1947601910368849","article-title":"Sanguinarine suppresses prostate tumor growth and inhibits survivin expression","volume":"1","author":"Sun","year":"2010","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1490","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.pbb.2008.05.010","article-title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures \u2014 A short review","volume":"90","author":"Sv\u00ed\u017eensk\u00e1","year":"2008","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1495","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1500","series-title":"Endocannabinoid signaling in neural circuits of the olfactory and limbic system, cannabinoids in health and disease","author":"Thomas","year":"2016"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009143","article-title":"THC prevents MDMA neurotoxicity in mice","volume":"5","author":"Tourino","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1510","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnbeh.2013.00100","article-title":"The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)","volume":"7","author":"Trezza","year":"2013","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1515","doi-asserted-by":"crossref","first-page":"449s","DOI":"10.1002\/j.1552-4604.1981.tb02625.x","article-title":"Electrophysiologic properties of the cannabinoids","volume":"21","author":"Turkanis","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington's disease: Studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1525","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1742-7843.2012.00881.x","article-title":"The CB(1) receptor antagonist, AM281, improves recognition loss induced by naloxone in morphine withdrawal mice","volume":"111","author":"Vaseghi","year":"2012","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/3-540-26573-2_12","article-title":"Retrograde signalling by endocannabinoids","author":"Vaughan","year":"2005","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1535","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3747\/co.23.3080","article-title":"Anticancer mechanisms of cannabinoids","volume":"23","author":"Velasco","year":"2016","journal-title":"Current Oncology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1540","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.physbeh.2007.11.012","article-title":"Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome","volume":"93","author":"Vemuri","year":"2008","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1545","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1550","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00520-002-0387-7","article-title":"Established and potential therapeutic applications of cannabinoids in oncology","volume":"11","author":"Walsh","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1555","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1560","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1073\/pnas.0336351100","article-title":"Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice","volume":"100","author":"Wang","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1565","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916663731","article-title":"Dopaminergic inhibition by G9a\/Glp complex on tyrosine hydroxylase in nerve injury-induced hypersensitivity","volume":"12","author":"Wang","year":"2016","journal-title":"Molecular Pain"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1570","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.seizure.2016.04.002","article-title":"Prognostic factors for seizure outcome in patients with MRI-negative temporal lobe epilepsy: A meta-analysis and systematic review","volume":"38","author":"Wang","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1575","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-5793(95)00027-7","article-title":"The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide","volume":"359","author":"Wartmann","year":"1995","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1580","series-title":"Cb-delta8\u2014Thc composition","author":"Webster","year":"2007"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1585","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)33364-1","article-title":"Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol","volume":"223","author":"Weissman","year":"1982","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1590","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1063545","article-title":"Endocannabinoid signaling in the brain","volume":"296","author":"Wilson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1595","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/jcb.21630","article-title":"Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue","volume":"104","author":"Yang","year":"2008","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1600","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1357-2725(98)00082-X","article-title":"Vascular endothelial growth factor","volume":"30","author":"Zachary","year":"1998","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1605","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.bjp.0707514","article-title":"delta9-Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors","volume":"152","author":"Zani","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1610","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/aps.2011.173","article-title":"Tools for GPCR drug discovery","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1615","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/acer.12845","article-title":"Effects of chronic alcohol exposure on the modulation of ischemia-induced glutamate release via cannabinoid receptors in the dorsal hippocampus","volume":"39","author":"Zheng","year":"2015","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1620","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00482-009-0816-3","article-title":"Long-term treatment with oral ketamine. Case report of a female patient with therapy-resistant post-herpetic neuralgia","volume":"23","author":"Zimmer","year":"2009","journal-title":"Schmerz"},{"key":"10.1016\/j.pharmthera.2017.06.003_bb1625","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-neuro-070815-014038","article-title":"Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation?","author":"Zlebnik","year":"2016","journal-title":"Annual Review of Neuroscience"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T23:31:08Z","timestamp":1750289468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817301511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":325,"alternative-id":["S0163725817301511"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}